Chronic kidney disease; International standardization; parathormone; standardization
Abstract :
[en] Background: Standardization of parathyroid hormone
(PTH) assays is a major issue, especially in hemodialyzed
(HD) patients. Two automated third generation
PTH assays (Roche Elecsys and DiaSorin Liaison) are now
available. These assays are specific for the (1-84) PTH and
do not cross-react with the (7-84) fragment, contrary to
second generation (intact) assays. We aimed to calibrate
the two methods against the WHO International PTH
Standard (IS) 95/646 to see if the two assays could provide
comparable results in a population of healthy subjects,
HD patients and patients suffering from primary hyperparathyroidism
(PHP).
Methods: We selected 79 healthy subjects and two populations
of patients presenting PTH disorders: 56 HD and 27
PHP patients. We reconstituted the IS in a pool of human
serum containing undetectable levels of 1-84 PTH and prepared
13 serum standards ranging from 0 to 2000 pg/mL.
The standards were run on the two instruments to calibrate
the assays on the IS. The different populations were
run before and after restandardization.
Results: As these kits were differently calibrated, the
results obtained after restandarization were significantly
different. Restandardization process improved concordance
between assays and, taking the analytical variability
of the two kits into account, the results could be considered
to be similar.
Conclusions: Restandardization of automated third
generation PTH assays with the WHO 1-84 PTH Standard
significantly reduces inter-method variability. Reference
ranges and raw values are totally transposable
from one method to the other in healthy subjects, but
also in diseased patients, e.g., with HD or those suffering
from PHP.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
LUKAS, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
CARLISI, Ignazia ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
GADISSEUR, Romy ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Souberbielle, Jean-Claude
Language :
English
Title :
Standardization of DiaSorin and Roche automated third generation PTH assays with an international standard: impact on clinical populations
Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta 2006;366:81-9.
Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 2005;26:78-113.
D'Amour P, Brossard JH. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005;14:330-6.
Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805-9.
Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345-50.
Hecking M, Kainz A, Bielesz B, Plischke M, Beilhack G, Hörl WH, et al. Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients. Clin Biochem 2012;45:1645-51.
Cavalier E, Delanaye P, Hubert P, Krzesinski JM, Chapelle JP, Rozet E. Estimation of the stability of parathyroid hormone when stored at-80 degrees C for a long period. Clin J Am Soc Nephrol 2009;4:1988-92.
Horowitz GL. Defining, establishing and verifying reference intervals in clinical laboratory; approved guideline, 3rd ed. Wayne, PA: CLSI, 2008.
Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results-A critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011;26:3440-5.
Almond A, Ellis AR, Walker SW. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2012;49:63-7.
Kumar V, Barnidge DR, Chen LS, Twentyman JM, Cradic KW, Grebe SK, et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 2010;56:306-13.
Miller WG, Myers GL, Rej R. Why commutability matters. Clin Chem 2006;52:553-4.
Marcus R, Madvig P, Young G. Age-related changes in parathyroid hormone and parathyroid hormone action in normal humans. J Clin Endocrinol Metab 1984;58:223-30.